David Maybee, MD
Pulmonary Disease · New Bern, NCNPI 1245286467
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,381 of the $15,338 with a category attached, or 74.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.8%. 2025 is the largest year on record at $4,895, 2.9 times the $1,706 reported in 2019.
Across 632 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$3K
- GSK$1K
- AstraZeneca$1K
- Inspire Medical Systems, Inc.$1K
- Insmed, Inc.$825
- Genentech USA, Inc.$748
- plus $7K from 54 others
Across 199 payments — averaging $4911.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$553K
- Boehringer Ingelheim$198K
- Chiesi USA, Inc.$184K
- Boehringer Ingelheim International GmbH$22K
- Sanofi US Services Inc.$18K
- Novartis$2K
What the payments were for
- Travel & lodging$3,53323%
- Food & beverage$11,38174%
- Education$4243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,338 in reported general payments places this provider in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $306,933 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 243 | $205,025 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 214 | $118,916 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 112 | $108,983 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 174 | $103,862 |
| Spiriva RespimatTiotropium Bromide | 118 | $79,014 |
| Dupixent PenDupilumab | 17 | $75,090 |
| Breo ElliptaFluticasone/Vilanterol | 123 | $66,034 |
| Arnuity ElliptaFluticasone Furoate | 129 | $37,790 |
| Ambrisentan | 13 | $37,050 |
| SymbicortBudesonide/Formoterol Fumarate | 97 | $33,491 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 76 | $32,619 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 129 | $21,400 |
| Advair HfaFluticasone Propion/Salmeterol | 47 | $19,400 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $15,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $672 | $505,742340 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,492 | $441,045748 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,391 | $175,092285 claims |
| MerckDulera | $229 | $4,03012 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $101 | $3,40115 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $24 | $2,24632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in New Bern
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.